174 related articles for article (PubMed ID: 8818347)
1. Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock.
Giral M; Balsa D; Ferrando R; Merlos M; Garcia-Rafanell J; Forn J
Br J Pharmacol; 1996 Jul; 118(5):1223-31. PubMed ID: 8818347
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new platelet-activating factor antagonist, UR-12670, on several endotoxic shock markers in rats.
Balsa D; Merlos M; Giral M; Ferrando R; Garcia-Rafanell J; Forn J
Drugs Exp Clin Res; 1997; 23(5-6):191-9. PubMed ID: 9515229
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of yangambin on cardiovascular hyporeactivity to catecholamines in rats with endotoxin-induced shock.
Araújo CV; Barbosa-Filho JM; Cordeiro RS; Tibiriçá E
Naunyn Schmiedebergs Arch Pharmacol; 2001 Mar; 363(3):267-75. PubMed ID: 11284440
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
5. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
6. ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats.
Albert DH; Luo G; Magoc TJ; Tapang P; Holms JH; Davidsen SK; Summers JB; Carter GW
Shock; 1996 Aug; 6(2):112-7. PubMed ID: 8856845
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
[TBL] [Abstract][Full Text] [Related]
9. Dissociation of TNF-alpha from endotoxin-induced nitric oxide and acute-phase hypotension.
Xie J; Joseph KO; Bagby GJ; Giles TD; Greenberg SS
Am J Physiol; 1997 Jul; 273(1 Pt 2):H164-74. PubMed ID: 9249487
[TBL] [Abstract][Full Text] [Related]
10. Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock.
Wu CC; Chen SJ; Szabó C; Thiemermann C; Vane JR
Br J Pharmacol; 1995 Apr; 114(8):1666-72. PubMed ID: 7541282
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock.
Casals-Stenzel J
Eur J Pharmacol; 1987 Mar; 135(2):117-22. PubMed ID: 3582490
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
[TBL] [Abstract][Full Text] [Related]
13. [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.
Carceller E; Merlos M; Giral M; Balsa D; Almansa C; Bartrolí J; García-Rafanell J; Forn J
J Med Chem; 1994 Aug; 37(17):2697-703. PubMed ID: 7914928
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of TCV-309--a potent PAF antagonist.
Terashita Z; Takatani M; Nishikawa K
J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598
[TBL] [Abstract][Full Text] [Related]
15. Interactions of constitutive nitric oxide with PAF and thromboxane on rat intestinal vascular integrity in acute endotoxaemia.
László F; Whittle BJ; Moncada S
Br J Pharmacol; 1994 Dec; 113(4):1131-6. PubMed ID: 7889265
[TBL] [Abstract][Full Text] [Related]
16. Effect of selective blockade of endothelin ETB receptors on the liver dysfunction and injury caused by endotoxaemia in the rat.
Ruetten H; Thiemermann C
Br J Pharmacol; 1996 Oct; 119(3):479-86. PubMed ID: 8894167
[TBL] [Abstract][Full Text] [Related]
17. Role for intracellular platelet-activating factor in the circulatory failure in a model of gram-positive shock.
De Kimpe SJ; Thiemermann C; Vane JR
Br J Pharmacol; 1995 Dec; 116(8):3191-8. PubMed ID: 8719795
[TBL] [Abstract][Full Text] [Related]
18. Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats.
Qi M; Jones SB
Circ Shock; 1990 Oct; 32(2):153-63. PubMed ID: 2253318
[TBL] [Abstract][Full Text] [Related]
19. Role of thromboxane A2 and platelet activating factor in early haemodynamic response to lipopolysaccharide in rats.
Bocheński J; Chłopicki S; Gryglewski RJ
J Physiol Pharmacol; 1999 Jun; 50(2):287-97. PubMed ID: 10424723
[TBL] [Abstract][Full Text] [Related]
20. Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration.
Pearson JM; Bailie MB; Fink GD; Roth RA
Toxicology; 1997 Sep; 121(3):181-9. PubMed ID: 9231696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
